In contrast, the most recent NCCN guidelines (version 1.2012) [62] recommend ALK rearrangement testing concurrent with EGFR mutation testing for adenocarcinomas, large cell carcinomas and NSCLC NOS. This evidence concerns the gene ALK and non-small cell lung carcinoma.